Summary
Global Markets Direct’s, ‘Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2016’, provides an overview of the Head And Neck Cancer Squamous Cell Carcinoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma
- The report reviews pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Head And Neck Cancer Squamous Cell Carcinoma therapeutics and enlists all their major and minor projects
- The report assesses Head And Neck Cancer Squamous Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AB Science SA
AbbVie Inc.
Acceleron Pharma, Inc.
Advaxis, Inc.
Altor BioScience Corporation
Amgen Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
Bionovis SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
CEL-SCI Corporation
Cellceutix Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Centrose LLC
Critical Outcome Technologies Inc.
Daiichi Sankyo Company, Limited
Debiopharm International SA
Eisai Co., Ltd.
Eli Lilly and Company
Etubics Corporation
F. Hoffmann-La Roche Ltd.
G&E Herbal Biotechnology Co., Ltd.
Genexine, Inc.
Genmab A/S
GlaxoSmithKline Plc
Gliknik, Inc.
Glycotope GmbH
Hanmi Pharmaceuticals, Co. Ltd.
Horizon Pharma Plc
Immunomedics, Inc.
Immunovative Therapies, Ltd.
Incyte Corporation
Innate Pharma S.A.
Inovio Pharmaceuticals, Inc.
IRX Therapeutics, Inc.
Kolltan Pharmaceuticals, Inc.
Laboratoires Pierre Fabre SA
Loxo Oncology, Inc.
Mabion SA
MacroGenics, Inc.
Marsala Biotech Inc.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Molecular Partners AG
Molplex Ltd.
Novartis AG
Oncobiologics, Inc.
Oncolytics Biotech Inc.
Onconova Therapeutics, Inc.
OncoSec Medical Incorporated
Ono Pharmaceutical Co., Ltd.
OXiGENE, Inc.
Panacea Biotec Limited
PCI Biotech Holding ASA
Pfizer Inc.
Sanofi
Shanghai Henlius Biotech Co., Ltd.
Shenzen SiBiono GeneTech Co., Ltd.
Shionogi & Co., Ltd.
Sillajen Biotherapeutics
Symphogen A/S
Synta Pharmaceuticals Corp.
Takara Bio Inc.
Threshold Pharmaceuticals, Inc.
UbiVac, LLC
VasGene Therapeutics, Inc.
VentiRx Pharmaceuticals, Inc.
Virttu Biologics Limited
Viventia Bio Inc.
Vyriad
'
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 11
Introduction 12
Global Markets Direct Report Coverage 12
Head And Neck Cancer Squamous Cell Carcinoma Overview 13
Therapeutics Development 14
Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview 14
Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis 15
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies 16
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 23
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance 24
Late Stage Products 24
Clinical Stage Products 25
Early Stage Products 26
Unknown Stage Products 27
Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies 28
Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes 37
Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development 38
AB Science SA 38
AbbVie Inc. 39
Acceleron Pharma, Inc. 40
Advaxis, Inc. 41
Altor BioScience Corporation 42
Amgen Inc. 43
AstraZeneca Plc 44
AVEO Pharmaceuticals, Inc. 45
Bayer AG 46
Bionovis SA 47
Boehringer Ingelheim GmbH 48
Bristol-Myers Squibb Company 49
CEL-SCI Corporation 50
Cellceutix Corporation 51
Celldex Therapeutics, Inc. 52
Celltrion, Inc. 53
Centrose LLC 54
Critical Outcome Technologies Inc. 55
Daiichi Sankyo Company, Limited 56
Debiopharm International SA 57
Eisai Co., Ltd. 58
Eli Lilly and Company 59
Etubics Corporation 60
F. Hoffmann-La Roche Ltd. 61
G&E Herbal Biotechnology Co., Ltd. 62
Genexine, Inc. 63
Genmab A/S 64
GlaxoSmithKline Plc 65
Gliknik, Inc. 66
Glycotope GmbH 67
Hanmi Pharmaceuticals, Co. Ltd. 68
Horizon Pharma Plc 69
Immunomedics, Inc. 70
Immunovative Therapies, Ltd. 71
Incyte Corporation 72
Innate Pharma S.A. 73
Inovio Pharmaceuticals, Inc. 74
IRX Therapeutics, Inc. 75
Kolltan Pharmaceuticals, Inc. 76
Laboratoires Pierre Fabre SA 77
Loxo Oncology, Inc. 78
Mabion SA 79
MacroGenics, Inc. 80
Marsala Biotech Inc. 81
MedImmune, LLC 82
Merck & Co., Inc. 83
Merck KGaA 84
Merrimack Pharmaceuticals, Inc. 85
Millennium Pharmaceuticals, Inc. 86
Mirati Therapeutics Inc. 87
Molecular Partners AG 88
Molplex Ltd. 89
Novartis AG 90
Oncobiologics, Inc. 91
Oncolytics Biotech Inc. 92
Onconova Therapeutics, Inc. 93
OncoSec Medical Incorporated 94
Ono Pharmaceutical Co., Ltd. 95
OXiGENE, Inc. 96
Panacea Biotec Limited 97
PCI Biotech Holding ASA 98
Pfizer Inc. 99
Sanofi 100
Shanghai Henlius Biotech Co., Ltd. 101
Shenzen SiBiono GeneTech Co., Ltd. 102
Shionogi & Co., Ltd. 103
Sillajen Biotherapeutics 104
Symphogen A/S 105
Synta Pharmaceuticals Corp. 106
Takara Bio Inc. 107
Threshold Pharmaceuticals, Inc. 108
UbiVac, LLC 109
VasGene Therapeutics, Inc. 110
VentiRx Pharmaceuticals, Inc. 111
Virttu Biologics Limited 112
Viventia Bio Inc. 113
Vyriad 114
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment 115
Assessment by Monotherapy Products 115
Assessment by Combination Products 116
Assessment by Target 117
Assessment by Mechanism of Action 130
Assessment by Route of Administration 137
Assessment by Molecule Type 139
Drug Profiles 141
ABBV-221 - Drug Profile 141
AdIL-24 - Drug Profile 142
afatinib dimaleate - Drug Profile 144
alisertib - Drug Profile 149
AlloVax - Drug Profile 154
alpelisib - Drug Profile 156
ALT-803 - Drug Profile 158
AMG-319 - Drug Profile 161
Antibodies to Inhibit FRMD4A for Oncology - Drug Profile 163
Antisense Oligonucleotide to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 164
AV-203 - Drug Profile 165
avelumab - Drug Profile 167
axalimogene filolisbac - Drug Profile 169
AZD-5069 - Drug Profile 174
AZD-6738 - Drug Profile 176
AZD-9150 - Drug Profile 178
bleomycin sulfate - Drug Profile 179
BMS-986016 - Drug Profile 182
BNV-003 - Drug Profile 183
buparlisib hydrochloride - Drug Profile 184
cabazitaxel - Drug Profile 188
capmatinib - Drug Profile 190
Cellular Immunotherapy for Oncology - Drug Profile 193
Cellular Immunotherapy to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 195
cetuximab - Drug Profile 196
cetuximab biobetter - Drug Profile 203
cetuximab biosimilar - Drug Profile 204
cetuximab biosimilar - Drug Profile 205
cetuximab biosimilar - Drug Profile 206
cetuximab biosimilar - Drug Profile 207
cetuximab biosimilar - Drug Profile 208
cetuximab biosimilar - Drug Profile 209
copanlisib hydrochloride - Drug Profile 210
COTI-2 - Drug Profile 214
dalantercept - Drug Profile 217
Debio-1143 - Drug Profile 219
depatuxizumab - Drug Profile 222
DNA IL-12 - Drug Profile 223
DPV-001 - Drug Profile 226
DTP-348 - Drug Profile 228
durvalumab - Drug Profile 229
durvalumab + tremelimumab - Drug Profile 234
E-10A - Drug Profile 236
E-7046 - Drug Profile 237
EBC-46 - Drug Profile 238
EDC-2 - Drug Profile 239
elgemtumab - Drug Profile 240
enoblituzumab - Drug Profile 242
epacadostat - Drug Profile 244
ETBX-041 - Drug Profile 246
everolimus - Drug Profile 247
ficlatuzumab - Drug Profile 254
futuximab - Drug Profile 257
ganetespib - Drug Profile 259
gedatolisib - Drug Profile 263
Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma - Drug Profile 265
Gene Therapy to Activate p53 for Oncology - Drug Profile 266
GL-0817 - Drug Profile 268
golvatinib tartrate - Drug Profile 270
GS-10 - Drug Profile 272
GSK-2636771 - Drug Profile 274
GSK-2849330 - Drug Profile 275
GSK-3174998 - Drug Profile 276
GX-051 - Drug Profile 277
HF-10 - Drug Profile 278
HSV-1716 - Drug Profile 280
IC-1001 - Drug Profile 283
INCB-50465 - Drug Profile 284
INO-3106 - Drug Profile 285
INO-3112 - Drug Profile 286
interferon gamma-1b - Drug Profile 288
IRX-2 - Drug Profile 291
JX-929 - Drug Profile 293
KGP-94 - Drug Profile 294
KM-3174 - Drug Profile 295
KTN-3379 - Drug Profile 299
lenvatinib mesylate - Drug Profile 301
Leukocyte Interleukin - Drug Profile 308
LGK-974 - Drug Profile 311
lirilumab - Drug Profile 312
LN-145 - Drug Profile 314
LOXO-101 - Drug Profile 316
lumretuzumab - Drug Profile 318
masitinib - Drug Profile 320
MEDI-0562 - Drug Profile 326
merestinib - Drug Profile 328
MGCD-265 - Drug Profile 329
MGD-009 - Drug Profile 332
monalizumab - Drug Profile 333
Monoclonal Antibodies to Antagonize Frizzled Receptors for Breast Cancer and Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile 335
Monoclonal Antibody to Target CD147 for Pancreatic Adenocarcinoma and Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 336
motolimod - Drug Profile 337
MP-0250 - Drug Profile 339
nilotinib - Drug Profile 341
nimotuzumab - Drug Profile 345
nivolumab - Drug Profile 349
NP-001 - Drug Profile 357
olaparib - Drug Profile 358
Oncolytic Virus to Activate IFN-b for Hepatocellular Carcinoma and Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile 362
Oncolytic Virus to Target CD46 for Recurrent Squamous Cell Carcinoma Head and Neck Cancer - Drug Profile 364
palbociclib - Drug Profile 365
panitumumab - Drug Profile 370
patritumab - Drug Profile 374
pelareorep - Drug Profile 376
pembrolizumab - Drug Profile 381
PF-04518600 - Drug Profile 392
PF-06801591 - Drug Profile 393
poziotinib - Drug Profile 394
prexasertib - Drug Profile 396
Recombinant Peptide to Target EGFR for Oncology - Drug Profile 398
Recombinant Protein for Oncology - Drug Profile 399
rigosertib sodium - Drug Profile 400
S-488210 - Drug Profile 406
sacituzumab - Drug Profile 407
SB-01 - Drug Profile 409
seribantumab - Drug Profile 411
SF-1126 - Drug Profile 414
Small Molecules for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 416
Small Molecules to Inhibit 16S rRNA for Head And Neck Cancer Squamous Cell Carcinoma and Oral Cancer - Drug Profile 417
Small Molecules to Inhibit CREB Protein for Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile 418
Small Molecules to Inhibit IL-6 for Head and Neck Squamous Cell Carcinoma - Drug Profile 419
solarise - Drug Profile 420
Synthetic Peptide for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 421
tarloxotinib bromide - Drug Profile 422
tisotumab vedotin - Drug Profile 424
trametinib dimethyl sulfoxide + uprosertib - Drug Profile 426
UBS-109 - Drug Profile 428
urelumab - Drug Profile 430
utomilumab - Drug Profile 432
varlilumab - Drug Profile 434
Vas-01 - Drug Profile 437
VB-4847 - Drug Profile 439
vinflunine ditartrate - Drug Profile 441
Head And Neck Cancer Squamous Cell Carcinoma - Recent Pipeline Updates 443
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects 687
Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products 691
Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones 693
Featured News & Press Releases 693
Appendix 702
Methodology 702
Coverage 702
Secondary Research 702
Primary Research 702
Expert Panel Validation 702
Contact Us 702
Disclaimer 703
List of Tables
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H1 2016 24
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H1 2016 25
Number of Products under Development by Companies, H1 2016 27
Number of Products under Development by Companies, H1 2016 (Contd..1) 28
Number of Products under Development by Companies, H1 2016 (Contd..2) 29
Number of Products under Development by Companies, H1 2016 (Contd..3) 30
Number of Products under Development by Companies, H1 2016 (Contd..4) 31
Number of Products under Development by Companies, H1 2016 (Contd..5) 32
Number of Products under Investigation by Universities/Institutes, H1 2016 33
Comparative Analysis by Late Stage Development, H1 2016 34
Comparative Analysis by Clinical Stage Development, H1 2016 35
Comparative Analysis by Early Stage Development, H1 2016 36
Comparative Analysis by Unknown Stage Development, H1 2016 37
Products under Development by Companies, H1 2016 38
Products under Development by Companies, H1 2016 (Contd..1) 39
Products under Development by Companies, H1 2016 (Contd..2) 40
Products under Development by Companies, H1 2016 (Contd..3) 41
Products under Development by Companies, H1 2016 (Contd..4) 42
Products under Development by Companies, H1 2016 (Contd..5) 43
Products under Development by Companies, H1 2016 (Contd..6) 44
Products under Development by Companies, H1 2016 (Contd..7) 45
Products under Development by Companies, H1 2016 (Contd..8) 46
Products under Investigation by Universities/Institutes, H1 2016 47
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AB Science SA, H1 2016 48
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AbbVie Inc., H1 2016 49
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H1 2016 50
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Advaxis, Inc., H1 2016 51
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Altor BioScience Corporation, H1 2016 52
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc., H1 2016 53
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AstraZeneca Plc, H1 2016 54
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 55
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bayer AG, H1 2016 56
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bionovis SA, H1 2016 57
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 58
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 59
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by CEL-SCI Corporation, H1 2016 60
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Cellceutix Corporation, H1 2016 61
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H1 2016 62
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celltrion, Inc., H1 2016 63
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Centrose LLC, H1 2016 64
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Critical Outcome Technologies Inc., H1 2016 65
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 66
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Debiopharm International SA , H1 2016 67
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eisai Co., Ltd., H1 2016 68
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eli Lilly and Company, H1 2016 69
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Etubics Corporation, H1 2016 70
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 71
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2016 72
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genexine, Inc., H1 2016 73
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genmab A/S, H1 2016 74
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H1 2016 75
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Gliknik, Inc., H1 2016 76
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Glycotope GmbH, H1 2016 77
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 78
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Horizon Pharma Plc, H1 2016 79
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunomedics, Inc., H1 2016 80
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunovative Therapies, Ltd., H1 2016 81
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Incyte Corporation, H1 2016 82
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Innate Pharma S.A., H1 2016 83
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 84
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by IRX Therapeutics, Inc., H1 2016 85
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016 86
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Laboratoires Pierre Fabre SA, H1 2016 87
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Loxo Oncology, Inc., H1 2016 88
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mabion SA, H1 2016 89
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MacroGenics, Inc., H1 2016 90
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Marsala Biotech Inc., H1 2016 91
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MedImmune, LLC, H1 2016 92
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck & Co., Inc., H1 2016 93
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck KGaA, H1 2016 94
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 95
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 96
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mirati Therapeutics Inc., H1 2016 97
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Molecular Partners AG, H1 2016 98
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Molplex Ltd., H1 2016 99
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG, H1 2016 100
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncobiologics, Inc., H1 2016 101
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H1 2016 102
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Onconova Therapeutics, Inc., H1 2016 103
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OncoSec Medical Incorporated, H1 2016 104
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 105
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OXiGENE, Inc., H1 2016 106
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Panacea Biotec Limited, H1 2016 107
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by PCI Biotech Holding ASA, H1 2016 108
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Pfizer Inc., H1 2016 109
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sanofi, H1 2016 110
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016 111
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016 112
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shionogi & Co., Ltd., H1 2016 113
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sillajen Biotherapeutics, H1 2016 114
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Symphogen A/S, H1 2016 115
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Synta Pharmaceuticals Corp., H1 2016 116
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Takara Bio Inc., H1 2016 117
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 118
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by UbiVac, LLC, H1 2016 119
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VasGene Therapeutics, Inc., H1 2016 120
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2016 121
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Virttu Biologics Limited, H1 2016 122
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Viventia Bio Inc., H1 2016 123
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Vyriad, H1 2016 124
Assessment by Monotherapy Products, H1 2016 125
Assessment by Combination Products, H1 2016 126
Number of Products by Stage and Target, H1 2016 128
Number of Products by Stage and Mechanism of Action, H1 2016 141
Number of Products by Stage and Route of Administration, H1 2016 148
Number of Products by Stage and Molecule Type, H1 2016 150
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H1 2016 453
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects, H1 2016 697
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..1), H1 2016 698
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..2), H1 2016 699
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..3), H1 2016 700
Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products, H1 2016 701
Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products (Contd..1), H1 2016 702
List of Figures
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H1 2016 24
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H1 2016 25
Number of Products under Development by Companies, H1 2016 26
Number of Products under Investigation by Universities/Institutes, H1 2016 33
Comparative Analysis by Late Stage Development, H1 2016 34
Comparative Analysis by Clinical Stage Development, H1 2016 35
Comparative Analysis by Early Stage Products, H1 2016 36
Assessment by Monotherapy Products, H1 2016 125
Assessment by Combination Products, H1 2016 126
Number of Products by Top 10 Targets, H1 2016 127
Number of Products by Stage and Top 10 Targets, H1 2016 127
Number of Products by Top 10 Mechanism of Actions, H1 2016 140
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 140
Number of Products by Top 10 Routes of Administration, H1 2016 147
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 147
Number of Products by Top 10 Molecule Types, H1 2016 149
Number of Products by Stage and Top 10 Molecule Types, H1 2016 149
